Monaco Asset Management SAM Sells 465,674 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)

Monaco Asset Management SAM lessened its stake in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) by 27.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,212,743 shares of the biotechnology company's stock after selling 465,674 shares during the quarter. Monaco Asset Management SAM owned about 0.80% of Heron Therapeutics worth $1,855,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in HRTX. Y Intercept Hong Kong Ltd acquired a new position in Heron Therapeutics in the 3rd quarter worth approximately $39,000. Capstone Investment Advisors LLC acquired a new position in Heron Therapeutics in the 3rd quarter worth approximately $45,000. King Wealth Management Group boosted its stake in Heron Therapeutics by 52.3% in the 3rd quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 8,000 shares during the period. Glenmede Trust Co. NA boosted its stake in Heron Therapeutics by 49.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 10,578 shares during the period. Finally, Cutter & CO Brokerage Inc. boosted its stake in Heron Therapeutics by 69.6% in the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company's stock worth $51,000 after purchasing an additional 13,600 shares during the period. Institutional investors and hedge funds own 80.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. StockNews.com lowered shares of Heron Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, March 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Friday, February 28th.

Remove Ads

Heron Therapeutics Trading Up 3.8 %

Shares of HRTX stock traded up $0.09 during trading hours on Tuesday, hitting $2.48. 2,305,343 shares of the company were exchanged, compared to its average volume of 2,361,974. The business has a 50 day moving average of $1.86 and a two-hundred day moving average of $1.74. Heron Therapeutics, Inc. has a 52 week low of $1.04 and a 52 week high of $3.93. The company has a market capitalization of $377.78 million, a PE ratio of -13.78 and a beta of 1.55.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.05. The business had revenue of $40.78 million for the quarter, compared to analyst estimates of $37.37 million. On average, research analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current year.

Heron Therapeutics Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.